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Simple Summary: Internal organs like the heart and lungs, and body cavities like the thoracic and
abdominal cavities, are covered by a thin, slippery layer called the mesothelium. Malignant pleural
mesothelioma (MPM) is an aggressive cancer of the lining of the lung, where genetics and asbestos
exposure play a role. It is not diagnosable until it becomes invasive, offering only a short survival
time to the patient. To help understand the role of the genes that relate to this disease most of which
are poorly understood, we constructed the ‘MPM interactome’, including in it the protein-protein
interactions that we predicted computationally and those that are previously known in the literature.
Five novel protein-protein interactions (PPIs) were tested and validated experimentally. 85.65% of the
interactome is supported by genetic variant, transcriptomic, and proteomic evidence. Comparative
transcriptome analysis revealed 5 repurposable drugs targeting the interactome proteins. We make
the interactome available on a freely accessible web application, Wiki-MPM.
Abstract: Malignant pleural mesothelioma (MPM) is an aggressive cancer affecting the outer lining
of the lung, with a median survival of less than one year. We constructed an ‘MPM interactome’ with
over 300 computationally predicted protein-protein interactions (PPIs) and over 2400 known PPIs of
62 literature-curated genes whose activity affects MPM. Known PPIs of the 62 MPM associated genes
were derived from Biological General Repository for Interaction Datasets (BioGRID) and Human
Protein Reference Database (HPRD). Novel PPIs were predicted by applying the HiPPIP algorithm,
which computes features of protein pairs such as cellular localization, molecular function, biological
process membership, genomic location of the gene, and gene expression in microarray experiments,
and classifies the pairwise features as interacting or non-interacting based on a random forest model.
We validated five novel predicted PPIs experimentally. The interactome is significantly enriched
with genes differentially ex-pressed in MPM tumors compared with normal pleura and with other
thoracic tumors, genes whose high expression has been correlated with unfavorable prognosis in
lung cancer, genes differentially expressed on crocidolite exposure, and exosome-derived proteins
identified from malignant mesothelioma cell lines. 28 of the interactors of MPM proteins are targets
of 147 U.S. Food and Drug Administration (FDA)-approved drugs. By comparing disease-associated
versus drug-induced differential expression profiles, we identified five potentially repurposable
drugs, namely cabazitaxel, primaquine, pyrimethamine, trimethoprim and gliclazide. Preclinical
studies may be con-ducted in vitro to validate these computational results. Interactome analysis of
disease-associated genes is a powerful approach with high translational impact. It shows how MPM-
associated genes identified by various high throughput studies are functionally linked, leading to
clinically translatable results such as repurposed drugs. The PPIs are made available on a webserver
with interactive user interface, visualization and advanced search capabilities.
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1. Introduction
Internal organs such as heart and lung, and body cavities such as thoracic and ab-
dominal cavities, are covered by a thin slippery layer of cells called the “mesothelium”.
This protective layer prevents organ adhesion and plays a number of important roles in
inflammation and tissue repair [1]. The mesothelia that line the heart, lung and abdominal
cavity are called pericardium, pleura and peritoneum, respectively. Mesothelioma is the
cancer that originates from this lining (described in detail in a recent review article [2]).
Most types of mesothelioma metastasize to different locations in the body [3]. Pleural
mesotheliomas account for ~90% of malignant mesotheliomas and have a short median
survival, of less than 1 year [4].
Malignant pleural mesothelioma (MPM) is associated with exposure to asbestos;
it has a long latency period after exposure and is conclusively diagnosable only after
reaching the invasive phase [3]. It tends to cluster in families and occurs only in a small
fraction of the population exposed to asbestos, suggesting the involvement of a genetic
component [5]. These factors necessitate expeditious discovery of genetic predispositions,
molecular mechanisms and therapeutics for the disease.
The molecular mechanisms of disease are often revealed by the protein-protein inter-
actions (PPIs) of disease-associated genes. For example, the involvement of transcriptional
deregulation in MPM pathogenesis was identified through mutations detected in BAP1
and its interactions with proteins such as HCF1, ASXL1, ASXL2, ANKRD1, FOXK1 and
FOXK2 [6]. PPI of BAP1 with BRCA1 was central to understanding the role of BAP1 in
growth-control pathways and cancer; BAP1 was suggested to play a role in BRCA1 stabiliza-
tion [7,8]. Studies on BAP1 and BRCA1 later led to clinical trials of the drug vinorelbine as
a second line therapy for MPM patients, and the drug was shown to have rare or moderate
effects in MPM patients [9,10]. BAP1 expression was shown to be necessary for vinorelbine
activity; 40% of MPM patients in a study showed low BRCA1 expression and vinorelbine
resistance [11–13]. Further, 60% of the disease-associated missense mutations perturb PPIs
in human genetic disorders [14].
Despite their importance, only about 10–15% of expected PPIs in the human protein
interactome are currently known; for nearly half of the human proteins, not even a single
PPI is currently known [15]. Due to the sheer number of PPIs remaining to be discovered
in the human interactome, it becomes imperative that biological discovery be accelerated
by computational and high-throughput biotechnological methods. We developed a com-
putational model, called HiPPIP (high-precision protein-protein interaction prediction)
that is deemed accurate by computational evaluations and experimental validations of
18 predicted PPIs, where all the tested pairs were shown to be true PPIs ([16,17] and current
work, and other unpublished works). HiPPIP computes features of protein pairs such as
cellular localization, molecular function, biological process membership, genomic location
of the gene, and gene expression in microarray experiments, and classifies the pairwise
features as interacting or non-interacting based on a random forest model [16]. Though
each of the features by itself is not an indicator of an interaction, a machine learning
model was able to use the combined features to make predictions with high precision. The
threshold of HiPPIP to classify a protein-pair as “a PPI” was set high in such a way that
it yields very high-precision predictions, even if low recall. Novel PPIs predicted using
this model are making translational impact. For example, they highlighted the role of cilia
and mitochondria in congenital heart disease [18,19], that oligoadenylate synthetase-like
protein (OASL) activates host response during viral infections through RIG-I signaling via
its PPI with retinoic acid-inducible gene I (RIG-I) [17], and led to the identification of drugs
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potentially repurposable for schizophrenia [20], one of which is currently under clinical
trials.
In this work, we studied MPM-associated genes and their PPIs assembled with HiPPIP
and analyzed the MPM interactome to draw translatable results. We demonstrate the
various ways in which systems-level analysis of this interactome could lead to biologically
insightful and clinically translatable results. We made the interactome available to the
cancer biology research community on a webserver with comprehensive annotations, so as
to accelerate biomedical research on MPM.
2. Results
We collected 62 MPM-associated genes from the Ingenuity Pathway Analysis (IPA)
suite, which will be referred to as ‘MPM genes’ here; these genes have been reported to
affect MPM through gene expression changes or genetic variants, or by being targeted by
drugs clinically active against MPM (see details in Data File S1) [21]. Previously known
PPIs of the 62 MPM genes were collected from Human Protein Reference Database (HPRD),
version 9 [22] and Biological General Repository for Interaction Datasets (BioGRID) version
4.3.194 [23]. Novel (hitherto unknown) PPIs were predicted with HiPPIP, a computational
model. We discovered 364 novel PPIs of MPM genes (Table 1), which are deemed highly
accurate according to prior evaluation of the HiPPIP model including experimental vali-
dations [16]. The MPM interactome thus assembled has 2459 known PPIs and 364 novel
PPIs among the 62 MPM-associated genes and 1911 interactors (Figure 1 and Data File
S2). Nearly half of the MPM genes had 10 or less known PPIs each, and about 130 novel
PPIs have been predicted for these (Figure 2). HiPPIP predicted 920 PPIs of which 556 PPIs
were previously known, leaving 364 PPIs to be considered as novel PPIs of the MPM
genes. There were an additional 1903 PPIs that are known and not predicted by HiPPIP.
This is as expected because the HiPPIP prediction threshold has been fixed to achieve
high precision by compromising recall, which is required for adoption into biology; in other
words, it is set to predict only a few PPIs out of the hundreds of thousands of unknown
PPIs, but those that are predicted will be highly accurate. It has to be noted that neither
PPI prediction nor high throughput PPI screening can be performed with high-precision
and high-recall. Co-immunoprecipitation (Co-IP) based methods show high-precision and
extremely-low recall (detecting only one PPI at a time), whereas multi-screen high-quality
yeast 2-hybrid methods show high-precision with low recall (detecting a few tens of thou-
sands of PPIs). Thus, HiPPIP is on par with other methods in terms of precision and the
number of new PPIs detected. 18 novel PPIs predicted by HiPPIP were validated to be true
(validations have been reported in [16,17], the current work and other unpublished works);
the experiments were carried out by diverse research labs.
Table 1. Novel Interactors of each of the malignant pleural mesothelioma (MPM) Genes: Number
of known (K) and computationally predicted novel (N) protein-protein interactions (PPIs) and lists
the novel interactors. Bold genes in the 4th column are Novel Interactors that were experimentally
validated in the current study.
Gene K N Novel Interactors
ATP1B1 21 7 HCRTR1, SERPINC1, TM4SF1, PRRX1, CD84, CREG1,THOC1
ATIC 5 5 MAP3K7, CPS1, KIAA1524, VWC2L, DES
ATXN1 287 5 CNOT6L, XPO7, C7, PITX3, RPL19
BAP1 27 2 PLN, PARP3
CDKN2A 168 5 NFX1, DNAI1, GLIPR2, SIT1, CA9
CTLA4 17 10 PLCL1, DCTD, SKP1, GLP1R, AOX1, CD28, ATP5G3,CLK1, BCS1L, CDC26
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Table 1. Cont.
Gene K N Novel Interactors
DHFR 10 7 RHOQ, SCZD1, TOMM7, EXOC4, DTYMK, COPS8,CRHBP
FGFR1 67 7 ZFYVE1, NRG1, TPMT, OR51B4, SHB, PPP2CB,EIF4EBP1
FGFR2 46 8 PTPRE, OAT, PLXNA1, SEC23IP, MDM2, MGMT,PLSCR1, ELK4
FGFR3 43 6 GRK4, GMPS, STK32B, IDUA, IRF2BPL, ADD1
FLT1 25 8 MIPEP, RASSF9, HMGB1, FLT3, LATS2, ALOX5AP,ARL2BP, CDK8
FLT3 17 8 FMO1, SNRPA1, PNPLA3, NFIB, GPR12, SHC1, FLT1,CDK8
FLT4 16 4 NKX2-5, HNRNPH1, GRIA1, PNPLA8
FOXO3 27 4 GPR6, HDAC2, PRDM13, SIM1
GART 4 5 TIAM1, NMI, TMPRSS15, JUN, IFNAR1
GIPR 2 0 None
HLA-DQA1 9 6 HLA-DQA2, KLHDC3, TAL2, NXF1, BRD2, HLA-DPB1
HSP90AA1 158 6 IGHA2, MED28, PHLDA2, TCIRG1, IGHD, USP13
HSP90AB1 59 10 SLC25A27, PENK, ZFP36L2, MTX2, TPSAB1, PROS1,GPRC5B, CCR7, GNPDA1, CETN3
HSP90B1 36 2 MMP17, EPB41L4B
IL4R 23 5 RBBP6, NPIPB5, SLC20A1, ERN2, HDGFRP3
KAZN 12 6 KIF1B, NPPA, CELA2A, CELA2B, CTRC, FBLIM1
KDR 60 8 UTP3, SRP72, SHOX2, KIT, ALB, CACNA1S, CHIC2,GSTA2
KRT5 25 10 SORD, KRT6A, NADSYN1, SAP18, KRT7, TARBP2,KRT6B, KRT4, DCTN1, GPD1
KRT72 19 8 SP7, KRT78, KRT80, LARP4, MYL6B, KRT74, BCDIN3D,GRASP
LCK 143 5 NCDN, ZSCAN20, YBX1, CITED4, CAMK1D
LY6E 6 8 PIP, GLI4, HSF1, AKR1B1, EIF3H, JRK, GML, GPAA1
LYN 125 12 NEK7, SGK3, PDCD4, TRPA1, TERF1, PNMA2, IL7,CLCF1, AGXT, ARFGEF1, CRH, KLHL41
NTRK2 34 3 NXNL2, KCNS1, CDK20
PDCD1 2 3 COPS8, MCL1, OR6B3
PDGFRA 64 4 SPOCK1, RAPGEF1, ALB, CD244
PDGFRB 76 8 PLAUR, TUFM, CDX1, CHRM3, FAXDC2, ITK, CDK14,MITF
PDPN 2 5 PRDM2, PRMT1, ZBTB48, CELA2B, LHX1
POLE 12 7 SCARB1, RAN, VSIG4, ULK1, EIF2B1, MMP17, NOS1
POLE2 19 6 SAV1, PYGL, NID2, PARK7, DRD3, ATOH1
POLE3 7 7 TNC, TRIM32, EIF4G2, ASTN2, GSN, CST3, ALAD
POLE4 7 4 REG3G, SGOL1, EVA1A, B4GALT4
PRR5 5 3 WNT7B, TTC38, SCUBE1
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Table 1. Cont.
Gene K N Novel Interactors
RRM1 10 12
SLC22A18AS, SIRPA, SLC22A18, STIM1, SPINK1,
ZFPM2, SH2D3A, PSMD13, RNH1, NUP98, CUZD1,
RGS4
RRM2 9 10 TAF1B, ST3GAL3, NPBWR2, LPIN1, GCG, MGAT4A,BARX1, ASAP2, ITSN2, LAPTM4A
SP1 146 5 HNRNPA1, REG1A, RAPGEF3, GRIN1, ENDOU
SRC 300 9 ZNF687, ENPP7, FMR1, PI3, PTPRT, CUL4B, DPYD,BARD1, PLTP
TARP 1 4 TBX20, GGCT, IL6, CPVL
TBCE 2 3 SERTAD3, EIF2B2, PRDM2
TTF1 6 3 AMPH, DFNB31, QRFP
TUBA1A 63 3 TUBA1C, AMHR2, ACVR1B
TUBA1C 63 8 PRKAG1, SHMT2, AMHR2, SCAF11, ACVR1B, AQP5,KMT2D, TUBA1A
TUBA3C 12 3 XPO4, EIF3FP2, PARP4
TUBA3D 1 6 TUBA3E, WTH3DI, CCDC74B, FAM168B, LOC151121,IMP4
TUBA4A 51 14
WNT6, ETV6, ATP5G3, CAPN2, CXCR1, SLC11A1,
CDK5R2, ALPP, IL1RL1, NUPR1, HPCA, SKP1, DPYSL2,
STK16
TUBA8 7 2 POTEH, CCT8L2
TUBB1 1 2 C20orf85, SLMO2
TUBB2A 27 0 None
TUBB3 34 6 PRDM7, SLC7A5, PIEZO1, MVD, TRAPPC2L, TCF25
TUBB4A 10 7 UQCR11, APC2, ABCA7, PLIN3, KDM4B, SBNO2,HMG20B
TUBB4B 19 4 TSC1, NELFB, C9orf9, PTPRE
TUBD1 1 6 TMED1, PTRH2, TRPV1, GJB3, EPX, RFX5
TUBE1 0 6 DPAGT1, NUDC, RPS20, CDC40, GOPC, C6orf203
TUBG1 28 6 WNT3, PHB, RND2, CTRL, SGCA, RARA
TUBG2 3 3 NBR2, IKZF3, CLMP
TYMS 3 9 YES1, TAF3, ITGAM, NDUFV2, EPB41L3, SMCHD1,OCRL, THOC1, NAPG
WT1 64 8 FJX1, PEX3, CAPRIN1, PAX6, BST2, B3GNT3, CALML5,HIPK3
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2.1. Experimental Validation of Selected Protein-Protein Interactions (PPIs)
We carried out experimental validations of five predicted PPIs chosen for their biologi-
cal relevance and proximity to MPM genes, namely, BAP1-PARP3, KDR-ALB, PDGFRA-ALB,
CUTA-HMGB1 and CUTA-CLPS. They were validated using protein pull-down followed
by protein identification using mass spectrometry (Table S1) or size-based protein detection
assay (Figure 3). Each bait protein was also paired with a random prey protein serving as
control (specifically, BAP1-phospholambin, ALB-FGFR2 and CUTA-FGFR2). All predicted
PPIs were validated to be true, while control pairs tested negative. In addition to these
five, another PPI from the MPM interactome, namely HMGB1-FLT1 was validated in our
prior work through co-immunoprecipitation [16]. Three novel PPIs, namely HLA-DQA1—
HLA-DQB1, FGFR2—FGF2 and CDKN2A—CDKN2B, that we reported in the preprint of
this work [24], have since been reported as known PPIs in a recent version of BioGRID
(downloaded February 2021); these three are treated as known PPIs in the remaining
description.
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Figure 3. Validation of predicted ALB interactions and CUTA interactions using Wes™ Simple West-
ern total protein detection assay: Pseudo-gel or virtual-blot like image of the validated interactions of
ALB (lanes 1–2) and CUTA (lanes 4, 7) along with negative control (lane 3). In addition to the final
pull-down samples, wash and/or flow through after binding ‘bait’ and ‘prey’ proteins for the CUTA
interactions are also shown (lanes 5, 6, 8 and 9). The electro-pherogram image of Simple Western
results using Total protein size-based assay. (A) ALB interactions with true positives KDR/VEGFR2,
PDGFRA and false positive FGFR2. (B) CUTA interactions with HMGB1. (C) CUTA interactions with
CLPS. An overlay of the electro-pherogram of the wash from HMGB1 after CUTA binding is also
shown in (C) for comparison.
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2.2. Functional Interactions of Malignant Pleural Mesothelioma (MPM) Genes with Predicted
Novel Interactors
We used ReactomeFIViz [25], a Cytoscape plugin, to extract known functional interac-
tions between MPM-associated genes and their novel interactors. Seven novel PPIs had
such functional interactions, namely (MPM genes are shown in bold), PDGFRB-RAPGEF1
(‘part of the same complex’, ‘bound by the same set of ligands’), SP1→HNRNPA1 (‘expression
regulation’), HLA-DQA1→HLA-DPB1, HLA-DQA2→HLA-DQA1 (‘part of the same complex’,
‘catalysis’), CTLA4-CD28, PDGFRB-PLAUR (‘bound by the same set of ligands’) and FGFR2-
MDM2 (‘ubiquitination’).
2.3. Web Server
We made the MPM interactome available on a webserver called Wiki-MPM (http:
//severus.dbmi.pitt.edu/wiki-MPM). It has advanced-search capabilities, and presents
comprehensive annotations, namely Gene Ontology, diseases, drugs and pathways, of the
two proteins of each PPI side-by-side. Here, a user can query for results such as “PPIs
where one protein is involved in mesothelioma and the other is involved in immunity”,
and then see the results with the functional details of the two proteins side-by-side. The
PPIs and their annotations also get indexed in major search engines like Google and Bing;
thus a user searching for ‘KDR and response to starvation’ would find the PPIs KDR-
CAV1 and KDR-ALB, where the interactors are each involved in ‘response to starvation’.
Querying by biomedical associations is a unique feature which we developed in Wiki-Pi
that presents known interactions of all human proteins [26]. Wiki-MPM is a specialized
version for disseminating the MPM interactome with its novel PPIs, visualizations and
browse features. The novel PPIs have a potential to accelerate biomedical discovery in
mesothelioma and making them available on this web server brings them to the biologists in
an easily-discoverable and usable manner. Wiki-MPM will be integrated into the National
Mesothelioma Virtual Bank [27,28], and will be available to the mesothelioma research
community as part of our translational support of cancer research.
2.4. Pathway Analysis
We compiled the list of pathways that any of the proteins of MPM interactome are
associated with, using Ingenuity Pathway Analysis suite [29]. Top 30 pathways by statistical
significance of association are shown in Figure 4A. A number of pathways such as NF-
κB signaling, PI3/AKT signaling, VEGF signaling and natural killer cell signaling, are highly
relevant to mesothelioma etiology. They are found to be connected to MPM genes through
novel PPIs that were previously unknown. For example, the PI3K/AKT signaling pathway
regulating the cell cycle is aberrantly active in MPM, and the mesothelioma gene FGFR1
is connected to this pathway via its novel predicted PPIs with EIF4EBP1 and PRP2CB
(Figure 4B) [30]. Statistical significance of association to the interactome, and various
MPM genes and novel interactors belonging to these pathways are shown in Table 2 and
Data File S3. A cancer biologist may utilize the Supplementary Data (Data Files S2 and S3)
to study novel PPIs that connect MPM genes to a pathway that they are interested in
studying.
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Table 2. Pathways that are relevant to the pathophysiology and genetics of malignant pleural mesothelioma: Pathway
analysis revealed that molecular mechanisms underlying various types of cancers, axonal guidance signaling, PI3/AKT
signaling, VEGF signaling, natural killer cell signaling and inflammation signaling pathways may be pertinent to the
development of MPM. A list of all the associated pathways is shown in Data File S3.
Pathway p-Value MPM Genes Novel Interactors
Glucocorticoid Receptor
Signaling 6.13 × 10
−56
KRT72, HSP90B1, FGFR3,
HSP90AB1, FGFR1, KRT5, FOXO3,
FGFR2, HSP90AA1
KRT74, HMGB1, PRKAG1, IL6,
KRT6B, KRT78, KRT80, KRT7, KRT4,
TAF3, NPPA, MAP3K7, KRT6A
Molecular Mechanisms of
Cancer 5.01 × 10
−53 CDKN2A, SRC, FGFR3, FGFR1,
FGFR2
CDK14, CDK20, CDKN2B, PRKAG1,
WNT7B, RND2, WNT6, CDK8,
RHOQ, RAPGEF3, MAP3K7, WNT3
NF-κB Signaling 1.26 × 10−39
FGFR1, LCK, FLT1, KDR, PDGFRA,
FGFR2, NTRK2, FGFR3, PDGFRB,
FLT4
MAP3K7
Small Cell Lung Cancer
Signaling 2.00 × 10
−37 FGFR1, FGFR2, FGFR3 CDKN2B
Axonal Guidance Signaling 2.51 × 10−37
TUBB1, TUBA1A, TUBA4A, TUBA8,
TUBB2A, NTRK2, FGFR3, FGFR1,
TUBB3, TUBG1, TUBA1C, TUBB4B,
FGFR2, TUBB4A
MYL6B, DPYSL2, PRKAG1, PLCL1,
WNT7B, WNT6, PLXNA1, TUBA3E,
WNT3
PI3K/AKT Signaling 1.58 × 10−36 HSP90B1, FOXO3, HSP90AA1,HSP90AB1 OCRL, PPP2CB, MCL1, EIF4EBP1
VEGF Signaling 3.98 × 10−36 FGFR1, FLT1, SRC, KDR, FOXO3,FGFR2, FGFR3, FLT4 EIF2B1, EIF2B2
Role of Macrophages,
Fibroblasts and Endothelial
Cells in Rheumatoid Arthritis
6.31 × 10−36 SRC, FGFR3, FGFR1, FGFR2
IL1RL1, IL6, PLCL1, WNT7B, IL7,
WNT6, CALML5, MAP3K7, WNT3,
APC2
Natural Killer Cell Signaling 6.31 × 10−32 FGFR1, LCK, FGFR2, FGFR3 OCRL, CD244
Actin Cytoskeleton Signaling 1.58 × 10−30 FGFR1, FGFR2, FGFR3 MYL6B, GSN, APC2
eNOS Signaling 3.16 × 10−30
FGFR1, FLT1, KDR, HSP90B1,
FGFR2, HSP90AA1, FGFR3, FLT4,
HSP90AB1
PRKAG1, CALML5, AQP5, CHRM3
Neuroinflammation Signaling
Pathway 3.98 × 10
−30 FGFR1, HLA-DQA1, FGFR2, FGFR3 HMGB1, HLA-DQB1, ACVR1B, IL6,GRIN1, GRIA1
Gap Junction Signaling 1.00 × 10−29
FGFR1, TUBB3, TUBG1, TUBB1,
TUBA1C, TUBA1A, SRC, TUBB4B,
TUBA4A, FGFR2, TUBA8, TUBB2A,
FGFR3, SP1, TUBB4A
GJB3, PRKAG1, TUBA3E, PLCL1,
GRIA1
Integrin Signaling 1.58 × 10−28 FGFR1, SRC, FGFR2, FGFR3 GSN, ITGAM, RHOQ, CAPN2,RND2
IL-6 Signaling 1.58 × 10−28 FGFR1, FGFR2, FGFR3 IL1RL1, MCL1, IL6, MAP3K7
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Figure 4. Pathways associated with malignant pleural mesothelioma (MPM) interactome: (A) Number of genes from MPM
interactome associated with various pathways are shown. Top 30 pathways based on significance of association with the
interactome are shown. (B) PI3K/AKT Signaling Pathway: Dark blue nodes are MPM genes, light blue nodes are known
interactors and red nodes are novel interactors. Nodes with purple labels are genes involved in the PI3K/AKT signaling
pathway.
2.5. Potentially Repurposable Drugs
We previously identified drugs potentially repurposable for schizophrenia through
interactome analysis, and one of them is currently in clinical trials (ClinicalTrials.gov
Identifier: NCT03794076) and another clinical trial has been funded and is yet to start [20].
Following this methodology, we constructed the MPM drug-protein interactome that shows
the drugs that target any protein in the MPM interactome. This analysis has been carried
out on an earlier version of BioGRID (3.4.159), which had fewer known PPIs, as reported in
the preprint version of the paper [24], and has not been recomputed with the latest version
of BioGRID unlike the other analyses presented here. There are 513 unique drugs that
target 206 of these proteins (of which 28 are novel interactors that are targeted by 147 drugs)
(Figure 5 and Data File S4). We adopted the established approach of comparing drug-
induced versus disease-associated differential expression using the BaseSpace correlation
software (previously called NextBio) [31,32], to identify five drugs that could be potentially
repurposable for MPM (Table 3; the table also shows corresponding information for two
known MPM drugs). These are: cabazitaxel, used in the treatment of refractory prostate
cancer; primaquine and pyrimethamine, two anti-parasitic drugs; trimethoprim, an antibiotic;
and gliclazide, an anti-diabetic drug (See Appendix A, titled ‘Repurposable Drugs for
Treatment of Malignant Pleural Mesothelioma’). The drugs were selected based on whether
they induced a differential expression (DE) in genes that showed a negative correlation
with lung cancer associated DE, and affected genes of high DE in MPM tumors/cell lines
(GSE51024 [33] and GSE2549 [34]), or underwent prior clinical testing in lung cancer.
Lung cancers share common pathways with mesothelioma initiated on asbestos exposure.
Therefore, drugs targeting lung cancers can potentially be used in MPM [35]. Table 3 shows
pharmacokinetic details of the drugs as reported in Drug Bank [36].
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Although in each case, there would be some genes that are differentially expressed
in the same direction for both the drug and the disorder (for e.g., both the drug and the
disease cause some genes to overexpress), the overall effect on the entire transcriptome
has an anti-correlation. A correlation score is generated based on the strength of the over-
lap between the drug and the disease datasets. Statistical criteria such as correction for
multiple hypothesis testing are applied and the correlated datasets are then ranked by
statistical significance. A numerical score of 100 is assigned to the most significant result,
and the scores of the other results are normalized with respect to this top-ranked result.
We excluded drugs with unacceptable toxicity (e.g., minocycline) or unsuitable pharma-
cokinetics. The final list comprised 15 drugs, out of which 10 have already been tested
against mesothelioma in clinical trials/animal models, and several of them were found to
display clinical activity [37–53] (Table S2). Gemcitabine and pemetrexed are being used
as first-line therapy for mesothelioma, in combination with cisplatin [45,53]. Ipilimumab
has been identified to be a potential second-line or third-line therapy in combination
with nivolumab [47]. Ixabepilone stabilizes cancer progression for up to 28 months [49].
Zoledronate, which showed modest activity in MPM, induced apoptosis and S-phase
arrest in human mesothelioma cells and inhibited tumor growth in an orthotopic animal
model [54,55]. Sirolimus/cisplatin increased cell death and decreased cell proliferation in
MPM cell lines [56]. α-Tocopheryl succinate increased the survival of orthotopic animal
models of malignant peritoneal mesothelioma [57]. Pre-clinical testing of vitamin E and its
analogs are in progress [58,59].
Primaquine targets KRT7, a novel interactor of KRT5, whose high expression has been cor-
related with tumour aggressiveness and drug resistance in malignant mesothelioma [60–62].
Primaquine may be re-purposed for MPM treatment at least as an adjunctive drug with
pemetrexed, the drug currently used for first-line therapy. Primaquine enhanced the sen-
sitivity of the multi-drug resistant cell line KBV20C to cancer drugs [63]. Gliclazide is an
anti-diabetic drug inhibiting VEGFA [64], a known interactor of KDR, and is significantly
upregulated in MPM tumour (Log2FC = 1.83, p-value = 0.0018). Glicazide inhibits VEGF-
mediated neovascularization [64]. High levels of VEGF have been correlated with both
asbestos exposure in MPM and advanced cancer [65,66]. Glibenclamide, a drug with a
similar mechanism of action as that of glicazide, increases caspase activity in MPM cell lines
and primary cultures, leading to apoptosis mediated by TRAIL (TNF-related apoptosis
inducing ligand) [67].
Eliminating those drugs which are being/have already been tested in mesothelioma
with varying results, we arrived at a list of five potentially repurposable drugs in the
descending order of negative correlation scores: pyrimethamine, cabazitaxel, primaquine,
trimethoprim and gliclazide (Table 3). Cabazitaxel targets the MPM genes, TUBB1 and
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TUBA4A, and was effective in treating non-small cell lung cancer (NSCLC) that was
resistant to docetaxel, a drug that targets TUBB1 along with other known interactors of
MPM genes [37]. Pyrimethamine and trimethoprim target the MPM gene TYMS involved
in folate metabolism, which was found to be differentially expressed in MPM tumors
(GSE51024 [33]) (log2FC = 1.82, p-value = 4.10 × 10−17). MPM tumors have been shown to
be responsive to anti-folates [68].
2.6. Analysis with Other High-Throughput Data
This section describes the overlap of the MPM interactome with various types of MPM-
related biological evidence. 1690 (85.65%) proteins in the interactome were supported by
genetic variant, transcriptomic, and proteomic evidence, and are listed in Data File S5.
Table 4 shows 48 novel interactors that had three or more pieces of biological evidence.
Table 4. Novel interactors in the malignant pleural mesothelioma (MPM) interactome with biological evidences related to
MPM. The table shows the following data in columns labeled A to F. (A) 48 novel interactors of MPM associated genes
that have been linked to four or more biological evidences related to MPM, namely, B1: high or medium gene expression
in lungs, B2: differential gene expression in MPM tumor versus other thoracic tumors, B3: differential gene expression
in MPM tumor versus normal adjacent pleural tissue, B4: differential gene expression in MPM tumors of epithelioid,
biphasic and sarcomatoid types, B5: differential gene methylation in MPM, B6: gene expression correlated with unfavorable
lung cancer prognosis, B7: differential gene expression on exposure to asbestos or asbestos-like particles, C: isolation as
exosome-derived proteins from malignant mesothelioma cell lines, D: differential protein abundance levels in epithelioid
and sarcomatoid types of malignant mesothelioma, and E: genetic variants in MPM. Last column, F, gives the total number
of sources of evidences for each gene. The complete list of biological evidence for all the genes in the interactome can be
found in Data File S5.
A B C D E F
Novel Interactor





Variants TotalB1 B2 B3 B4 B5 B6 B7
CAPRIN1       6
RAN       6
TNC       6
CUL4B      5
GMPS      5
IL6      5
MGMT      5
NFIB      5
NUDC      5
PLAUR      5
PLIN3      5
PLXNA1      5
PRMT1      5
RNH1      5
SCARB1      5
SLC7A5      5
SMCHD1      5
ASAP2     4
B4GALT4     4
CAPN2     4
CDC40     4
DTYMK     4
EIF3H     4
EPB41L3     4
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A B C D E F
Novel Interactor





Variants TotalB1 B2 B3 B4 B5 B6 B7
EXOC4     4
GNPDA1     4
HNRNPA1     4
HNRNPH1     4
LARP4     4
MGAT4A     4
MITF     4
NDUFV2     4
OAT     4
PHB     4
PHLDA2     4
PLCL1     4
PRKAG1     4
PROS1     4
PTRH2     4
PYGL     4
RBBP6     4
SEC23IP     4
SGK3     4
SHMT2     4
SLC20A1     4
TCIRG1     4
XPO4     4
YBX1     4
We compiled the list of genes harboring MPM-associated genetic variants from Bueno et al. [5],
and compared this list with all the genes in the MPM interactome (i.e., MPM-associated
genes, their known and novel interactors) to identify overlaps. 275 genes in the MPM
interactome harbored either germline mutations, or somatic single nucleotide variants
(SNVs) or indels (insertions or deletions) (Figure 6, Table 4 and Data File S5) associated
with MPM tumors. Of these 275 genes, 37 were novel interactors of MPM genes. MGMT
carried germline mutations while the following carried somatic mutations: ASTN2, BARX1,
BRD2, CALML5, CAPRIN1, CLK1, CPS1, DPYD, EIF3H, EPB41L3, GMPS, GPR12, ITGAM,
KIAA1524, KMT2D, KRT4, MGAT4A, NBR2, NDUFV2, NFIB, NFX1, NUDC, PLCL1, PRDM2,
PRKAG1, PRMT1, PTPRT, PTRH2, RBBP6, SGK3, SLC20A1, SMCHD1, SPOCK1, TMPRSS15,
TNC and XPO4. Fourteen of these interact with MPM genes that also harbored a genetic
variant (MPM genes are shown in bold): CDKN2A-NFX1, FLT1-LATS2, TUBA3C-XPO4,
PDGFRA-SPOCK1, TYMS-SMCHD1, TYMS-EPB41L3, GART-TMPRSS15, TYMS-NDUFV2,
TYMS-ITGAM, RRM2-BARX1, RRM2-MGAT4A and ATIC-CPS1, ATIC-KIAA1524 and
POLE-NOS1.
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sue, namely, ACVR1B, IL6, MGMT, NRG1, OAT, PHLDA2, PLAUR and TNC (Table S3). 
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genes with black border have both genetic variants and gene/protein expression changes associated with them. The gene
expression-associated features include differential expression in MPM tumors versus normal adjacent pleura, MPM tumors
versus other thoracic tumors, differential gene methylation (affecting gene expression) in MPM tumors, gene expression
correlated with unfavorable lung cancer prognosis, differential gene expression on exposure to asbestos or asbestos-like
particles and high/medium expression i nor al lungs. The protein expression-associated feat res include i olation as
exosome-derived proteins from alignant mesothelioma cell lines and differential protein abu dan e levels in epithelioid
and sarcomatoid types of malignant mesothelioma. The complete list of genes in the interactome and their corresponding
evidence can be found in Data File S5.
We collected the methylation profile of pleural mesothelioma [69], and f und 8 novel
int ractors to be hypomethylated in pleural mesothelioma versus non-tumor pleur l tissue,
na ly, ACVR1B, IL6, MGMT, NRG1, OAT, PHLDA2, PLAUR and TNC (Tabl S3). Some
of them have little or no expression in lung tissue but e overexpressed in MPM. PLAUR
is a prognostic biomarker of MPM [70]. Similarly, FGFR1 and its novel interactor NRG1
had elevated mRNA expression in H2722 mesothelioma cell lines and in MPM tissue,
both contributing to increased cell growth under tumorigenic conditions [71,72]. TNC,
involved in invasive growth, is a prognostic biomarker overexpressed in MPM, having
low expression in normal lung tissues [73,74]. Thus, these novel interactors, which are
not normally expressed in lung tissue, may be hypomethylated in MPM leading to their
overexpression, contributing to MPM etiology.
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Three hundred and ninety three (393) genes in the MPM interactome were also dif-
ferentially expressed in mesothelioma tumors versus normal pleural tissue adjacent to
tumor (GSE12345 [75]) (p-value of overlap = 9.525 × 10−19, odds ratio = 1.51). 52 out of
the 314 novel interactors in the interactome were differentially expressed in this dataset
(p-value = 0.046, odds ratio = 1.26). 938 genes, including 132 novel interactors, in the inter-
actome were found to be differentially expressed in MPM tumors of epithelioid, biphasic
and sarcomatoid types versus paired normal tissues (GSE51024 [33]) (p-value of overlap
= 1.415 × 10−18, odds ratio = 1.24). Genes with fold-change >2 or < 12 were considered as
overexpressed and underexpressed, respectively, at a p-value < 0.05. Similarly, 744 genes in
the MPM interactome were differentially expressed in MPM tumors versus other thoracic
cancers such as thymoma and thyroid cancer (GSE42977 [76]) (p-value = 3.04 × 10−41,
odds ratio = 1.53). 112 out of the 314 novel interactors in the interactome were differentially
expressed in this dataset (p-value = 7.77 × 10−6, odds ratio = 1.45). This shows that the
MPM interactome is enriched with genes whose expression helps in distinguishing MPM
from other thoracic tumors and also with genes differentially expressed in mesothelioma
tumors versus normal pleural tissue (Figure 6 and Data File S5). From RNA-seq data in
GTEx, we found that 1311 genes, including 189 novel interactors, in the interactome have
high/medium expression in normal lung tissue (median transcripts-per-million (TPM) > 9)
(Figure 6 and Data File S5) [77].
A recent study had examined the gene expression profiles from the lungs of mice ex-
posed to asbestos fibers (crocidolite and tremolite), an asbestiform fiber (erionite) and a min-
eral fiber (wollastonite) [78]. Crocidolite, tremolite and erionite are capable of inducing lung
cancer and mesothelioma in humans and animal models [78]. On the other hand, wollas-
tonite is a low pathogenicity fiber that shows no association with the incidence of lung can-
cer and mesothelioma in humans, or carcinogenesis in animal models [79]. The MPM inter-
actome showed significant enrichment with all the 4 fibers (Figure 6 and Data File S5). The
highest statistical significance was shown for the human orthologs of the mouse genes that
were differentially expressed upon crocidolite exposure (199 genes, p-value = 1.16 × 10−18,
odds ratio = 1.88). This was followed by tremolite (47 genes, p-value = 2.445 × 10−5,
odds ratio = 1.87), wollastonite (16 genes, p-value = 0.0037, odds ratio = 2.09) and erionite
(10 genes, p-value = 0.025, odds ratio = 2.01). Altogether, 245 genes in the interactome,
including 29 novel interactors, have transcriptomic evidence with respect to exposure to
asbestos or asbestos-like fibers. These novel interactors are: ALB, B4GALT4, CAPN2, CDC40,
DES, FMO1, FMR1, GML, GRIA1, HMG20B, HNRNPA1, ITSN2, LARP4, LPIN1, MGAT4A,
NEK7, NFIB, NRG1, OCRL, PAX6, PDCD4, PITX3, PTRH2, REG3G, TAF1B, THOC1, TMED1,
TNC and XPO4.
From data in Pathology Atlas, we found that high expression of 73 genes, including
that of 10 novel interactors, in the interactome has been positively correlated with unfavor-
able prognosis for lung cancer (p-value = 1.72 × 10−9, odds ratio = 2.05) [80]. These novel
interactors are: SPOCK1, SLC7A5, SCARB1, PLIN3, PLAUR, PIEZO1, KRT6A, GJB3, B3GNT3
and ARL2BP. We predicted ARL2BP to interact with FLT1, a VEGF receptor expressed in
MPM cells. VEGF level in MPM patients is a biomarker for unfavorable prognosis, and
lung cancer tumors expressing FLT1 have been associated with poor prognosis [81,82].
Exosomes are extracellular vesicles secreted into the tumor microenvironment. They
facilitate immunoregulation and metastasis by shuttling cellular cargo and directing inter-
cellular communication. In a proteomic profiling study, 2176 proteins were identified in
exosomes of at least one of the four human malignant mesothelioma cell lines (JO38, JU77,
OLD1612 and LO68) [83]. 324 proteins in the MPM interactome appeared among these
exosome-derived proteins (p-value = 8.86 × 10−10, odds ratio = 1.36), out of which 47 were
novel interactors. Six hundred and thirty one (631) exosome-derived proteins were identi-
fied in all four malignant mesothelioma cell lines. Out of these, 127 occurred in the MPM
interactome (p-value = 4.54 × 10−12, odds ratio = 1.84), out of which 15 were novel interac-
tors (PRKAG1, HNRNPA1, HNRNPH1, SORD, RNH1, RAN, PYGL, SLC7A5, RPS20, PARP4,
YBX1, DCTN1, TUFM, EXOC4 and GNPDA1). In the following novel PPIs, both proteins
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involved in the interaction appeared among exosome-derived proteins (MPM gene in the
interaction is shown in bold): TUBB3-SLC7A5, HSP90AB1-PROS1, HSP90AB1-GNPDA1,
TUBB4A-PLIN3, LYN-ARFGEF1, HSP90AA1-PHLDA2, HSP90AA1-TCIRG1, TUBG1-PHB,
GART-NMI, SRC-CUL4B and ATIC-CPS1.
We computed the overlap of the interactome with 142 proteins that showed significant
differences in abundance levels between epithelioid and sarcomatoid types of diffuse
malignant mesothelioma [84]. In that study, a Fourier transform infrared (FTIR) imaging
approach was employed to identify pathologic regions from diffuse malignant mesothe-
lioma tissue samples [84]. These pathologic regions were then harvested using laser capture
microdissection for proteomic analysis. 32 proteins in the interactome were more abundant
in either epithelioid or sarcomatoid subtypes (p-value = 5.16 × 10−5, odds ratio = 2.06),
including six novel interactors (p-value = 0.038, odds ratio = 2.43). The novel interactors
KRT78, NDUFV2, PRMT1, RAN and RNH1—predicted to interact with the MPM genes
KRT72, TYMS, PDPN, POLE and RRM1, respectively—had higher abundance in epithelioid
samples, whereas IGHA2—predicted to interact with HSP90AA1—had higher abundance
in sarcomatoid samples. The predicted interactions of these protein biomarkers with MPM-
associated genes provide a mechanistic basis for experimental dissection of their ability to
act as factors differentiating epithelioid tumors from sarcomatoid tumors (and vice versa).
3. Discussion
Currently, mesothelioma biologists only study a handful of genes, such as BAP1,
CDKN2A and NF2. To shed light onto the other MPM-associated genes, whose functions
remain poorly characterized, we assembled the ‘MPM interactome’ with ~2400 previously
known PPIs and 364 computationally predicted PPIs (five of which have been validated
in this work), which along with their biological annotations are being made available to
researchers. We demonstrate the power of interactome-scale analyses to generate biologi-
cally insightful and clinically translatable results. The interactome has highly significant
overlaps with MPM-associated genetic variants, genes differentially expressed or methy-
lated in MPM or upon asbestos exposure, genes whose expression has been correlated with
lung cancer prognosis, and with exosome-derived proteins in malignant mesothelioma cell
lines. The interactome was enriched in cancer-related pathways. We extended the MPM
interactome to include the drugs that target any of its proteins and analyzed it to identify a
shortlist of 5 drugs that can potentially be repurposed for MPM—an example of a clinically
translatable result.
We validated in vitro five novel PPIs in the interactome, namely, BAP1-PARP3, ALB-
KDR, ALB-PDGFRA, CUTA-HMGB1 and CUTA-CLPS. Literature evidence shows that these
PPIs may be viable candidates for further experimentation in MPM cell lines or animal
models. We hypothesize that the BAP1-PARP3 interaction may enhance cancer growth
in MPM. BAP1 is a tumor suppressor protein playing a role in cell cycle progression,
repair of DNA breaks, chromatin remodeling, and gene expression regulation; variants
in BAP1 have been implicated in hereditary and sporadic mesothelioma [85]. PARP3 is
involved in DNA repair, regulation of apoptosis, and maintenance of genomic stability
and telomere integrity [86]. Interaction of BAP1 with BRCA1 has been shown to inhibit
breast cancer growth [7]. In the absence of BRCA1 activity or with a perturbation in
its interaction with BAP1, cancerous growth is enhanced [87]. Loss of BRCA1 protein
expression has been noted in MPM [12]. In this scenario, it is possible that the novel
interaction of BAP1 with PARP3 in cancerous cells may be promoting cancerous growth,
possibly through regulation of DNA repair and apoptosis. BAP1 and PARP3 were found
to be moderately overexpressed in sarcomatoid MPM tumors compared with normal
pleural tissue (log2FC = 0.575, p-value = 0.028, and log2FC = 0.695, p-value = 0.0212,
respectively) (GSE42977 [76]). Perturbation of the interaction of BAP1 with PARP3, using
PARP3 inhibitors, may then suppress cancerous growth, at least in sarcomatoid MPM.
Several studies and clinical trials [87], have shown that PARP inhibitors influence cancers
in which mutations in BRCA1 or BRCA2 are observed, which led us to assume that the
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cancerous growth-inhibiting interaction of BAP1 with BRCA1 may already be perturbed in
this case, and that PARP inhibitors may actually be blocking the novel interaction of BAP1
with PARP3 which enhances cancer growth. It has been pointed out that upon inhibiting
PARP activity, cancerous cells that lack BRCA1 or BRCA2 activity may undergo cell cycle
arrest and apoptosis, possibly due to an accumulation of chromatid aberrations and an
inability to perform DNA repair in the absence of BRCA [7,87]. Thus, we suspect that the
novel interaction of BAP1 and PARP3 may also be perturbed by PARP inhibitors, leading
to inhibition of cancer growth.
Low levels of ALB have been correlated with poor prognosis in MPM patients [88]. The
two MPM genes, KDR and PDGFRA, that ALB is predicted to interact with, are members of
the PI3K/AKT pathway which has been shown to be aberrantly active in mesothelioma [89].
High expression of CUTA has been correlated with favorable prognosis in lung cancer
(Pathology Atlas). It was found to be overexpressed in MPM tumors versus normal pleura
(log2FC = 0.871, p-value = 0.0039) (GSE2549 [34]). CLPS inhibits metastasis of the melanoma
cell line, B16F10, to lungs by blocking the signaling pathway involving β1 integrin, FAK
and paxillin [90]. CLPS has a novel interaction with NEDD9, which has been shown to
mediate β1 integrin signaling and promote metastasis of non-small lung cancer cells [91].
CD26, a cancer stem cell marker of malignant mesothelioma, has been shown to associate
with the integrin α5β1 (or ITGA5, a novel interactor of the MPM gene, FGFR2) and promote
cell migration and invasion in mesothelioma cells [91]. Another cancer stem cell marker of
malignant mesothelioma, CD9, inhibits this metastatic effect mediated by CD26. Depletion
of CD26 and CD9 was shown to respectively lead to decreased and increased expression
of NEDD9 and FAK in mesothelioma cells lines, hinting at the involvement of NEDD9
in mesothelioma tumor invasiveness [91]. NEDD9 has a known interaction with LYN,
an MPM gene, shown to play a negative role in the regulation of integrin signaling in
neutrophils [92]. CUTA has a novel interaction with HMGB1, which has been shown to
activate the integrin αMβ2 (or ITGAM, a novel interactor of the MPM gene, TYMS) and the
cell adhesion and migratory function of neutrophils mediated by αMβ2 [93]. HMGB1 also
has a novel interaction with the MPM gene, FLT1, shown to be involved in the migration of
multiple myeloma cells by associating with β1 integrin, and mediating PKC activation [94].
A recent bioinformatics study identified the genes differentially expressed in epithe-
lioid MPM tissues versus normal pleural tissues (GSE42977 [76]), and extracted the known
PPIs interconnecting these genes from the STRING database [95]. They identified 10 hub
genes from this network and shortlisted 31 drugs targeting the proteins in the network
based on scores from the Drug-Gene Interaction Database (DGIdb). The DGIdb score takes
into account the literature evidence for a particular drug-protein interaction, the number
of proteins in the network that interact with the given drug, and the ratio of the average
number of known protein interactors for all drugs compared to the number of known
protein interactors for the given drug. CDK1, which is one of the hub genes identified
in their study, is a known interactor of three MPM-associated genes, namely, LYN, SP1
and RRM2, and we showed that it has association to MPM in three omics datasets: high
expression correlated with unfavorable lung cancer prognosis, differential expression in
MPM tumors versus adjacent pleural tissue, and isolation as an exosome-derived protein in
malignant mesothelioma cell lines. Our work overall presents a more comprehensive study
in terms of a larger number of MPM genes analyzed, which were compiled from multiple
sources by IPA, and analysis of a larger number of MPM associated omics data sets, and
presents transcriptomic-driven shortlisting of repurposable drugs for which additional
evidence is presented from clinical trial data, literature, and differential expression of target
genes in MPM datasets.
Our study provides an integrative and mechanistic framework for functional transla-
tion of mesothelioma-related multi-omics data. The novelty of our work stems from two
key factors: (a) we present computationally predicted PPIs of high precision, which link
MPM-related genes from disparate genetic-variant / transcriptomic/proteomic studies in
hitherto unknown ways within the functional landscape of the interactome, and (b) the
Cancers 2021, 13, 1660 19 of 29
richly annotated MPM interactome is made available on a webserver to facilitate analysis
by biologists and computational systems biologists. Our approach has some limitations.
The drug-associated expression profiles analyzed in this study were induced in a diverse
set of cell lines rather than in mesothelioma cell lines. The effect of the proposed drugs
should be examined in MPM cell lines or animal models. We reported the overlap of
mouse genes differentially expressed upon asbestos exposure [78] with corresponding
human orthologs in the interactome. Mouse models have been routinely used to study
pathologic changes associated with asbestos exposure, including gene expression, and
these findings have been extrapolated to human diseases such as mesothelioma [96–99].
Nevertheless, our results should be interpreted with caution. It is not possible to draw
direct transcriptomic/proteomic/phenotypic equivalences between mice and humans,
unless these levels are comprehensively characterized in both the species, and a clear
equivalence of factors defining a condition such as asbestos exposure is demonstrated in
both the species [100]. Next, it is beyond the scope of our expertise to validate the large
number of computationally predicted PPIs in a tissue or cell line of interest. However,
we demonstrated the validity of computational predictions on a small number of PPIs
on purified proteins with appropriate controls. The computational model has also been
validated through additional experiments previously; some of the novel PPIs predicted
previously by our method have translated into results of biomedical significance [17–19].
4. Methods
4.1. Data Collection
A search using the keyword “malignant pleural mesothelioma” on IPA (Ingenuity
Pathway Analysis) retrieved genes causally related to the disease. IPA retrieves genes from
the Ingenuity Knowledge Base which has ~5 million experimental findings expert-curated
from biomedical literature or incorporated from other databases [29].
4.2. High-Precision Protein-Protein Interaction Prediction (HiPPIP) Model
PPIs were predicted by computing features of protein pairs, namely, cellular localiza-
tion, molecular function and biological process membership, genomic location of the gene,
gene expression from microarray experiments, protein domains and tissue membership
of proteins, as described in Thahir et al. [101], and developing a random forest model
to classify the pairwise features as interacting or non-interacting. A random forest with
30 trees was trained using the feature offering maximum information gain out of four
random features to split each node; minimum number of samples in each leaf node was set
to be 10. The random forest outputs a continuous valued score in the range of [0,1]. The
threshold to assign a final label was varied over the range of the score for positive class
(i.e., 0 to 1) to find the precision and recall combinations that are observed.
4.3. Evaluation of PPI Prediction Model
Evaluations on a held-out test data showed a precision of 97.5% and a recall of 5% at
a threshold of 0.75 on the output score. Next, we created ranked lists for each of the hub
genes (i.e., genes that had >50 known PPIs), where we considered all pairs that received
a score >0.5 to be novel interactions. The predicted interactions of each of the hub genes
are arranged in descending order of the prediction score, and precision versus recall is
computed by varying the threshold of predicted score from 1 to 0. Next, by scanning these
ranked lists from top to bottom, the number of true positives versus false positives was
computed.
4.4. Novel PPIs in the MPM Interactome
Each MPM gene, say Z, is paired with each of the other human genes (G1, G2 . . . GN),
and each pair is evaluated with the HiPPIP model. The predicted interactions of each of the
MPM genes (namely, the pairs whose score is >0.5) were extracted. These PPIs, combined
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with the previously known PPIs of MPM genes collectively form the ‘MPM interactome’.
Interactome figures were created using Cytoscape [102].
Note that 0.5 is the threshold chosen not because it is the midpoint between the two
classes, but because the evaluations with hub proteins showed that the pairs that received
a score >0.5 are highly confident to be interacting pairs. This was further validated through
experiments for a few novel PPIs above this score.
4.5. Previously Known PPIs in the MPM Interactome
Previously known PPIs of the 62 MPM genes were collected from Human Protein
Reference Database (HPRD) version 9 [22] and Biological General Repository for Interaction
Datasets (BioGRID) version 4.3.194 [23]. The data behind our web-server will be updated
once in a year with recent versions of BioGRID, and if novel PPIs are shown validated by
such updates to known PPIs, the information will be posted on the web-server.
4.6. In Vitro Pull-Down Assays
An initial screening to find physical interactions was performed using an in vitro pull-
down assay for some of the predicted novel PPIs. This technique utilizes a His/biotin tag-
fused protein immobilized on an affinity column as the bait protein and a passing-through
solution containing the ‘prey’ protein that binds to the ‘bait’ protein. The subsequent
elution will pull down both the target (prey) and tagged-protein (bait) for further analysis
by immunoblotting to confirm the predicted interactions. The pull-down assays were
conducted using the Pull-Down PolyHis Protein:Protein Interaction Kit (Pierce™, Rockford,
IL, USA) according to the manufacturer’s instructions.
4.7. Protein Identification Methods
Peptide sequencing experiments were performed using an EASY-nLC 1000 coupled to
a Q Exactive Orbitrap Mass Spectrometer (Thermo Scientific, San Jose, CA, USA) operating
in positive ion mode. An EasySpray C18 column (2 µm particle size, 75 µm diameter by
15 cm length) was loaded with 500 ng of protein digest in 22 µL of solvent A (water, 0.1%
formic acid) at a pressure of 800 bar. Separations were performed using a linear gradient
ramping from 5% solvent B (75% acetonitrile, 25% water, 0.1% formic acid) to 30% solvent
B over 120 min, flowing at 300 nL/min.
The mass spectrometer was operated in data-dependent acquisition mode. Precursor
scans were acquired at 70,000 resolution over 300–1750 m/z mass range (3e6 AGC target,
20 ms maximum injection time). Tandem MS spectra were acquired using HCD of the
top 10 most abundant precursor ions at 17,500 resolution (NCE 28, 1e5 AGC target, 60 ms
maximum injection time, 2.0 m/z isolation window). Charge states 1, 6–8 and higher were
excluded for fragmentation and dynamic exclusion was set to 20.0 s.
Mass spectra were searched for peptide identifications using Proteome Discoverer 2.1
(Thermo Scientific, Waltham, MA, USA) using the Sequest HT and MSAmanda algorithms,
peptide spectral matches were validated using Percolator (target FDR 1%). Initial searches
were performed against the complete UniProt database (downloaded 19 March 2018). Pep-
tide matches were restricted to 10 ppm MS1 tolerance, 20 mmu MS2 tolerance, and 2 missed
tryptic cleavages. Fixed modifications were limited to cysteine carbamidomethylation,
and dynamic modifications were methionine oxidation and protein N-terminal acetylation.
Peptide and protein grouping and results validation was performed using Scaffold 4.8.4
(Proteome Software, Portland, OR, USA) along with the X! Tandem algorithm against the
previously described database. Proteins were filtered using a 99% FDR threshold.
4.8. Ingenuity Pathway Analysis
Pathway associations of genes in the MPM interactome were computed using Ingenu-
ity Pathway Analysis (IPA). Statistical significance of the overlaps between genes in the
MPM interactome and pathways in the Ingenuity Knowledge Base (IKB) was computed
with Fisher’s exact test based on hypergeometric distribution. In this method, p-value is
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computed from the probability of k successes in n draws (without replacement) from a
finite population of size N containing exactly k objects with an interesting feature, where
N = total number of genes associated with pathways in IKB, K = number of genes associ-
ated with a particular pathway in IKB, n = number of genes in the MPM interactome and
k = K ∩ n. This value was further adjusted for multiple hypothesis correction using the
Benjamini-Hochberg procedure.
4.9. Analysis of Differential Gene Expression in Pleural Mesothelioma Tumors and Lungs of
Asbestos-Exposed Mice Versus Normal Tissue in Lungs
The overlap of the MPM interactome with genes differentially expressed in pleural
mesothelioma tumors compared with normal pleural tissue adjacent to mesothelioma
was computed using the dataset GSE12345 [75]. Genes differentially expressed in the
lungs of mice exposed to crocidolite and erionite fibers were obtained from the dataset
GSE100900 [78]. Genes with fold change >2 or 12 were considered as significantly overex-
pressed and underexpressed respectively at p-value < 0.05.
4.10. Analysis of DNA Methylation in MPM Tumors
The dataset GSE16559 [69] was used to analyze the methylation profile of pleural
mesotheliomas. In this study, genes found to be differentially methylated in mesothelioma
were identified from a set of 773 cancer-related genes associated with 1413 autosomal CpG
loci. Methylation values (M-values) were computed as M = log2 (β (1−β)) for both control
(non-tumor pleural tissue) and test (pleural mesothelioma) cases, where β is the ratio of
methylated probe intensity and overall intensity. Difference between M-values of test
and control cases was then computed, and genes with M-value > 1 and M-value < 1 were
considered to be hypermethylated and hypomethylated respectively at p-value < 0.05.
4.11. Correlating Expression of MPM Genes with Lung Cancer Prognosis
Data for correlation of gene expression and fraction of patient population surviving
after treatment for lung cancer was taken from the Pathology Atlas [80]. Genes with log-
rank p-value < 0.001 were considered to be prognostic. Unfavorable prognosis indicates
positive correlation of high gene expression with reduced patient survival.
4.12. Identification of Repurposable Drugs in the MPM Drug-Protein Interactome
Negative correlation between lung cancer and drugs were studied using the BaseSpace
correlation software, which uses a non-parametric rank-based approach to compute the
extent of enrichment of a particular set of genes (or ‘bioset’) in another set of genes [31].
Readers may refer to Appendix A, titled ‘Repurposable Drugs for Treatment of Malig-
nant Pleural Mesothelioma (MPM)’ for more details on the methodology used to identify
repurposable drugs.
5. Conclusions
Biomedical discovery in the field of MPM research has to be accelerated to fuel
clinically translatable results due to an urgent need to diagnose MPM preemptively, prevent
its post-treatment recurrence, and curb its predicted increase in incidence in western and
economically emerging nations [103]. In this study, we presented the MPM interactome as
a valuable resource for mesothelioma biologists. We demonstrated its biological validity
through comparison with MPM-related multi-omics data, which served to contextualize
the novel PPIs within the mesothelioma landscape. Making novel MPM PPIs available
freely on a webserver will catalyze investigations into these by cancer biologists and may
lead to biologically or clinically translatable results. The MPM interactome with disease-
associated proteins and their interacting partners will help biologists, bioinformaticians
and clinicians to piece together an integrated view on how MPM-associated genes from
various studies are functionally linked. Biological insights from this ‘systems-level’ view
will help generate testable hypotheses and clinically translatable results. Future work
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will focus on expanding this interactome by including interactions from additional PPI
repositories, other mesothelioma types and mesothelioma datasets.
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Appendix A Repurposable Drugs for Treatment of Malignant Pleural Mesothelioma
(MPM)
We present here five drugs (cabazitaxel, pyrimethamine, trimethoprim, primaquine and
glicazide) that could potentially be repurposed for the treatment of malignant pleural
mesothelioma (MPM). These drugs were shortlisted through three types of analysis: (A)
considering those that were already tested in non-small cell lung cancer (NSCLC), (B)
gene expression analysis of drugs that target MPM genes or novel interactors in the MPM
interactome, or (C) gene expression analysis of drugs that target known interactors in
the malignant pleural mesothelioma (MPM) interactome. Drugs were selected based on
whether they were already tested against lung cancer in clinical trials and/or showed
overall negative correlation with lung cancer expression studies, because both mesothe-
lioma and lung cancers have been shown to share common pathways that are initiated on
exposure to asbestos fibres in mesothelial cells and lung epithelial cells respectively [35].
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Another criterion used was whether the genes targeted by the drugs showed high differen-
tial expression in MPM tumours/cell lines. The details of these methods and observations
are presented below.
Appendix A.1 Repurposable Drugs Already Tested in Non-Small Cell Lung Cancer
Nine overlapping drugs were found between drugs tested in NSCLC and drugs
occurring in the MPM drug-protein interactome, that were negatively correlated with
lung cancer expression studies, namely, cabazitaxel, dasatinib, docetaxel, gemcitabine,
ipilimumab, ixabepilone, minocycline, pazopanib and pemetrexed. Minocycline was
eliminated due to its toxicity. All of the remaining eight drugs were found to be effective in
treatment of NSCLC (Table S2). Out of these eight drugs, cabazitaxel was the only drug
that was not tested for treatment of mesothelioma. The fact that the other seven drugs
were already tested against mesothelioma in clinical trials demonstrates the validity of our
approach. It was interesting to note that drugs that targeted known interactors in addition
to some MPM genes were found to have either no effect or limited clinical activity in
mesothelioma, for e.g., dasatinib, docetaxel and pazopanib. On the other hand, drugs that
targeted only MPM genes were found to be effective in treatment of mesothelioma or were
capable of preventing disease progression, for e.g., gemcitabine, ipilimumab, ixabepilone
and pemetrexed. This raises the suspicion that drugs that do not act on “off-target” genes
(known interactors, in this case) may be more effective. In this respect, cabazitaxel, which
targets the MPM genes TUBB1 and TUBA4A, may be a suitable candidate for mesothelioma.
Cabazitaxel was found to be effective in treatment of NSCLC resistant to docetaxel, a drug
that targets TUBB1 and other known interactors [37].
Appendix A.2 Repurposable Drugs Targeting MPM Genes and Novel Interactors
The MPM genes that were most differentially expressed with high significance in MPM
tumors (GSE51024 [33]) were TYMS (log2FC = 1.82, p-value = 4.10 × 10−17) and DHFR
(log2FC = 0.89, p-value = 1.20 × 10−14), and the drugs that target these genes (also having
negative correlation with lung cancer expression) were pyrimethamine and trimethoprim.
The first line drug currently used to treat mesothelioma is premetrexed, which targets
proteins in the folate metabolic pathway, namely, DHFR, TYMS and GART [104]. Since
MPM tumors have been shown to be responsive to anti-folates [68], both pyrimethamine
(which targets only DHFR) and trimethoprim (which targets both DHFR and TYMS), seem
to be interesting candidates. Pyrimethamine, an anti-parasitic drug commonly used to
treat toxoplasmosis and cystoisosporiasis, has shown anti-tumor activity in metastatic
melanoma cells and in murine models of breast cancer [105,106]. Trimethoprim, an anti-
bacterial drug commonly used in the treatment of urinary bladder and respiratory tract
infections, is also used to treat bacterial infections in cancer patients [107,108].
Keratin proteins form important components of the cell cytoskeleton, called intermedi-
ate filaments, in epithelial cells, and are commonly used as diagnostic markers in cancer [60].
In addition to their role as cancer markers, their involvement in cellular functions such
as cell motility, proliferation, cell polarity, protein synthesis, membrane trafficking and
most importantly, tumour invasion and metastasis make them attractive as candidates for
drug development [60]. KRT7 is a keratin primarily expressed in mesothelial cells, apart
from cells lining ducts and the intestine [60]. In a patient with malignant mesothelioma
of the epithelioid type (which spreads to mediastinum and breast), KRT7 was found to be
significantly overexpressed when she developed resistance to pemetrexed/carboplatin,
provided as a second line therapy [61]. The cancer cells showed a drastic increase in their
immunoreactivity to CK7, the protein encoded by KRT7 [61]. At the last stage of cancer
progression (which was followed by her death), the patient showed dyspnoea (difficulty
in breathing), increased tumour volume and pleural fluid [61]. In another case, KRT7 was
found be significantly overexpressed in an aggressive state of MPM, prior to treatment [61].
Two-thirds of malignant mesothelioma cases have been reported to be K7+/K20− (pos-
itive for expression of KRT7 and negative for expression of KRT20) [60]. Expression of
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KRT7 in three histological types of mesothelioma, namely, epithelioid, sarcomatid and
biphasic, has been used to distinguish them from synovial sarcoma that metastasizes
to the lungs and pleura [62]. KRT7 has been identified as marker of circulating tumour
cells in lung cancer [109]. KRT7 was also found to be significantly upregulated in MPM
tumours (log2FC = 3.80, p-value = 0.0002), and in cell line models of MPM (log2FC = 2.266,
p-value = 0.029) (GSE2549 [34]). Positive expression of KRT7 was noted in various types
of non-small cell lung cancers, including large cell neuroendocrine carcinoma and lung
adenocarcinoma [110,111]. In the MPM interactome, KRT7 was predicted to interact with
KRT5, an MPM gene that serves as a marker for malignant mesothelioma, along with vi-
mentin, and is specifically used to distinguish pleural mesothelioma of the epithelioid type
from pulmonary adenocarcinoma and non-pulmonary adenocarcinoma metastasizing to
pleura [60,112]. KRT7 is a target of primaquine, an-antimalarial agent known to destroy the
malarial parasites, Plasmodium vivax and Plasmodium ovale, inside the liver [113,114]. The
exact mechanism of action has not been elucidated for this drug. However, in independent
studies, primaquine has been shown to bind to keratin in a concentration-dependent man-
ner, and also mediate strong membrane perturbations in cell membrane models [113,115].
Since high expression of KRT7 has been shown to be related to tumour aggressiveness
and drug resistance in malignant mesothelioma, and its high expression was also noted in
MPM tumours and cell lines, primaquine may be re-purposed for treatment of MPM at
least as an adjunctive drug with pemetrexed, the drug currently used for first line therapy.
It is interesting to note that primaquine enhanced the sensitivity of KBV20C cells to cancer
drugs, namely, vinblastine, vinorelbine, paclitaxel, docetaxel, vincristine and halaven [63].
KVB20C is a multi-drug resistant cell line derived from oral squamous carcinoma. Pri-
maquine compounds (substituted quinolines) have also been shown to exert anti-tumor
activity in breast cancer cells [116].
Appendix A.3 Repurposable Drugs Targeting Known Interactors
Out of the four drugs targeting known interactors in the MPM interactome and show-
ing negative correlation with lung cancer associated gene expression, three drugs were al-
ready known to exhibit anti-tumour activity in pre-clinical models of mesothelioma, namely,
zoledronate, sirolimus and the vitamin E analog, alpha-tocopheryl succinate, which shows
the validity of our approach. Zoledronate, which showed modest activity in MPM, induced
apoptosis and S-phase arrest in human mesothelioma cells and inhibited tumor growth in
the pleural cavity of an orthotopic animal model [54,55]. Sirolimus/cisplatin increased cell
death and decreased cell proliferation in cell lines of MPM [56]. Alpha-tocopheryl succinate
increased survival of orthotopic animal models of malignant peritoneal mesothelioma [57].
Zoledronate has demonstrated modest clinical activity in patients with advanced MPM [54].
Sirolimus has not been tested against MPM in clinical trials, but everolimus, a drug derived
from sirolimus sharing similar properties with it, has shown only limited clinical activity
in MPM, and further testing as a single-agent was not advised based on the results from
this study [117]. Both vitamin E and its analog, alpha-tocopheryl succinate have not been
tested against MPM in clinical trials. However, testing of vitamin E and its analogs are
being carried out in various pre-clinical settings [58,59]. Hence, it was the drug gliclazide
that emerged as a potentially repurposable drug, untested against MPM.
Gliclazide, an anti-diabetic drug, inhibits VEGFA, which has been shown to be signifi-
cantly upregulated (Log2FC = 1.83, p-value = 0.0018) in MPM tumour (GSE2549 [34]). This
drug inhibits VEGF expression induced by advanced glycation end products in bovine
reticular endothelial cells, and VEGF expression induced by ischemia in retinal tissue
of mice [64,118]. In the latter case, glicazide also inhibits neovascularization, a process
known to be mediated by VEGF. VEGF has been identified as a prognostic marker for
MPM. High levels of VEGF have been correlated with both asbestos exposure in MPM,
and an advanced stage of the disease [65,66]. It is interesting to note that glibenclamide, a
drug whose mechanism of action is similar to that of glicazide, has been shown to increase
caspase activity in MPM cell lines and primary cultures, leading to apoptosis mediated by
Cancers 2021, 13, 1660 25 of 29
TNF-related apoptosis inducing ligand (TRAIL) [67]. Hence, glicazide may be repurposed
to inhibit neovascularization and perhaps enhance apoptosis in MPM.
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